Iris BioTechnologies (IRSB) Stock Price, News & Analysis

Company Overview

Iris BioTechnologies (OTCMKTS:IRSB) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for disorders of bone and mineral metabolism. The company’s research is centered on selective activators of TRPV5 and TRPV6 calcium channels, aiming to address conditions such as osteoporosis, hypercalciuria and kidney stones. By modulating calcium transport pathways, Iris BioTechnologies seeks to provide targeted treatments that improve bone density and reduce urinary calcium losses.

Founded in 2018 and headquartered in Irvine, California, Iris BioTechnologies has built a multidisciplinary team of scientists specializing in ion channel biology, medicinal chemistry and translational medicine. Its lead candidate, IBS-101, is currently in preclinical development with an emphasis on safety and efficacy in models of postmenopausal bone loss. The company also maintains collaborations with academic laboratories in North America and Asia to advance its understanding of calcium homeostasis and to accelerate the development of its pipeline.

In addition to its core R&D activities, Iris BioTechnologies has established strategic partnerships with contract research organizations for toxicology and formulation studies, and it engages regulatory consultants to prepare for future clinical trials. The company’s integrated approach combines computational drug design, high-throughput screening and in vivo validation to streamline candidate selection and optimize pharmacological profiles.

Leadership at Iris BioTechnologies is composed of industry veterans with extensive experience in biopharmaceutical development. The executive team is led by Chief Executive Officer Dr. Zara Miller, a former director of ion channel research at a global pharmaceutical firm, and Chief Scientific Officer Dr. Frank Delgado, a recognized expert in calcium channel physiology. Guided by a board of directors with backgrounds in venture capital, clinical development and regulatory affairs, Iris BioTechnologies is advancing toward its goal of bringing first-in-class therapies to patients suffering from debilitating bone and mineral disorders.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.04 to $0.41
• Volume: N/A
• Average Volume: 8,024 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IRSB Stock Analysis - Frequently Asked Questions

How have IRSB shares performed this year?

Iris BioTechnologies' stock was trading at $0.04 at the beginning of 2025. Since then, IRSB shares have increased by 0.0% and is now trading at $0.04.

How were Iris BioTechnologies' earnings last quarter?

Iris BioTechnologies Inc (OTCMKTS:IRSB) issued its quarterly earnings data on Tuesday, November, 15th. The company reported ($0.01) EPS for the quarter.

How do I buy shares of Iris BioTechnologies?

Shares of IRSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/15/2016
• Today: 7/15/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:IRSB
• Previous Symbol: NASDAQ:IRSB
• CIK: 1396238
• Web: www.irisbiotech.com
• Phone: +1-408-8672885
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A